by support | Nov 28, 2022 | Uncategorized
Aradigm, the company that submitted Linhaliq to the FDA for approval, announced that they had received a complete response letter (CRL) from the FDA stating that they would not approve the treatment at this time. Many of you have communicated recently with the FDA...
by support | Nov 28, 2022 | Uncategorized
NTM Info & Research and the COPD Foundation is happy to announce the release of the Bronchiectasis and NTM Information Line: 1-833-411-LUNG (5864). The Bronchiectasis and NTM Information Line is a toll-free number managed by the C.O.P.D. Information Line for...
by support | Nov 28, 2022 | Uncategorized
On April 8th, 2019 the U.S. Food & Drug Administration will host a public workshop on the development of antibacterial drugs for the treatment of nontuberculous mycobacterial (NTM) infection.
by support | Nov 28, 2022 | Uncategorized
The FDA workshop on “The Development of Antibiotics for the Treatment of NTM Disease” on April 8, 2019 was very successful, with more than 100 people attending in person. The agenda focused on issues surrounding clinical trials and the development of a validated...
by support | Nov 28, 2022 | Uncategorized
Dear Friends of NTM Info & Research, It is with a mixture of gratitude and sadness that I announce the retirement of Philip Leitman as President of NTM Info & Research. Philip, who co-founded NTMir with his late wife, Fern, will continue as President Emeritus...